Elan wins appeal in patent suit

ELN said the U.S. Court of Appeals for the Federal Circuit issued a decision affirming a previous court judgment that its Nifedipine extended-release product, a generic equivalent to BAYG's hypertension drug Adalat, do not infringe BAYG's U.S. Patent No. 5,264,446. ELN received FDA approval for Nifedipine in March, and the 30 mg tablets are being distributed by Biovail (BVF) through its U.S. marketing partner Teva (TEVA). ...